S ugie et al. evaluated postoperative mediastinal radiotherapy(MRT) for invasive thymoma with low-dose entire hemithorax radiotherapy (EHRT) for pleural dissemination. 1 This was done to clarify the role of EHRT.
However, this is not the entire story of EHRT use for thymomas. M. Uematsu et al. evaluated prophylactic EHRT in addition to MRT following a complete resection of stages II and III invasive thymoma. Forty-three patients had a complete surgical resection and then received EHRT ϩ MRT or MRT alone. In most cases, EHRT was 15 Gy/15 fractions over 3 weeks (without inhomogeneity corrections). In both the EHRT ϩ MRT and MRT group, the total radiation doses to the mediastinum were similar with a median of 40 Gy. Only one of the 23(4%) patients with EHRTϩMRT relapsed compared with eight of the 20(40%) with MRT. The pleura was the most common site of failure. At 5 years, the relapse-free rate was 100% for those receiving EHRTϩMRT compared with 66% with MRT (p ϭ 0.03). The overall survival rate was 96% for those with EHRT ϩ MRT compared with 74% for those with MRT (p ϭ not significant). The only significant treatment-related complication was radiation pneumonitis requiring treatment in one (5%) of the 20 patients who received MRT and three (13%) of 23 who received EHRT ϩ MRT. They concluded that except for elderly patients (who they felt were predisposed to toxicity), "EHRT ϩ MRT following a macroscopically complete resection appeared to be safe and feasible, and reduced intrathoracic relapses." 2 Yoshida et al. evaluated 11 thymoma patients with thoracic dissemination and less than complete resection. RT was administered postoperatively in all patients. RT doses ranged from 10 to 17 Gy to the entire hemithorax of the disseminated site and from 30 to 55 Gy to the primary tumor bed. Chemotherapy of various types was administered prior to RT in 7 cases. The 5-and 10-year survival rates were 80 and 64%, respectively. Six of the 11 patients were free from recurrence with a median follow-up of 60 months. EHRT was suggested as postoperative or definitive treatment for most patients with pleural spread of thymoma. 3 Thus, it is difficult with the available data to be show that EHRT ϩ MRT significantly improve the survival of patients who have had complete resection compared with MRT alone based on the studies of Sugie et al. and Uematsu et al. 1, 2 However, for patients who have had less than a complete resection, EHRT ϩ RT appear to salvage a large fraction of patients with pleural dissemination. 3 Based on the large French Experience of Cowen et al., four factors were associated with poorer survival: mediastinal compression on presentation (p Ͻ 0.001), absence of chemotherapy (p Ͻ 0.001), biopsy alone (p ϭ 0.003), and young age (p ϭ 0.013). Thus, an overall treatment plan should integrate resection (which should be as complete as possible) with RT for given invasive thymomas going beyond the capsule, 4 and chemotherapy used for those with advanced disease (stage III-IVa disease and mediastinal compression on presentation). Chemotherapy and/or RT can also be used preoperatively to potentially improve resectability. 5, 6 
